1.99

6.99% 0.13

Kyverna Therapeutics Inc (KYTX)

Panoramica Notizia Cronologia dei prezzi Forum Previsione

Precedente Chiudi:

$1.86

Aprire:

$1.82

Volume 24 ore:

263.62K

Relative Volume:

0.78

Capitalizzazione di mercato:

$96.38M

Reddito:

Utile/perdita netta:

$-110.66M

Rapporto P/E:

-0.6427

EPS:

-3.0963

Flusso di cassa netto:

$-97.76M

1 W Prestazione:

-10.76%

1M Prestazione:

-16.39%

6M Prestazione:

-61.73%

1 anno Prestazione:

-89.07%

Intervallo 1D:

$1.82

$2.05

Intervallo di 1 settimana:

$1.78

$2.2556

Portata 52W:

$1.78

$19.67

Kyverna Therapeutics Inc Stock (KYTX) Company Profile

Nome

Kyverna Therapeutics Inc

Settore

Healthcare (1155)

Industria

Biotechnology (677)

Telefono

(510) 626-8331

Indirizzo

5980 HORTON STREET, EMERYVILLE

Dipendente

119

Cinguettio

Prossima data di guadagno

Ultimi documenti SEC

KYTX's Discussions on Twitter

Confronta KYTX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
KYTX Kyverna Therapeutics Inc	1.99	96.38M	0	-110.66M	-97.76M	-3.0963
VRTX Vertex Pharmaceuticals Inc	477.52	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	561.49	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	595.70	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	232.75	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	229.22	26.16B	3.81B	-644.79M	-669.77M	-6.24

Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-10-10	Iniziato	UBS	Buy
2024-10-09	Iniziato	Rodman & Renshaw	Buy
2024-07-03	Iniziato	H.C. Wainwright	Neutral
2024-03-04	Iniziato	JP Morgan	Overweight
2024-03-04	Iniziato	Leerink Partners	Outperform
2024-03-04	Iniziato	Morgan Stanley	Overweight
2024-03-04	Iniziato	Wells Fargo	Overweight

Mostra tutto

Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie

Apr 20, 2025

JPMorgan Chase & Co. Sells 220,915 Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) - MarketBeat

Apr 20, 2025

4,126,119 Shares in Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Bought by Gilead Sciences Inc. - MarketBeat

Apr 20, 2025

Apr 19, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 19, 2025

Apr 18, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Shares Sold by Franklin Resources Inc. - MarketBeat

Apr 18, 2025

Apr 17, 2025

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode - Bluefield Daily Telegraph

Apr 17, 2025

Notice to Long-Term Shareholders of Kyverna Therapeutics, - GlobeNewswire

Apr 17, 2025

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR)Grabar Law Office Is Investigating Claims - TradingView

Apr 17, 2025

Apr 16, 2025

Investigation announced for Long-Term Investors in shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) - openPR.com

Apr 16, 2025

Apr 15, 2025

Robbins LLP Reminds Kyverna Therapeutics, Inc. Investors of the Pending Securities Fraud Class Action Against KYTX - marketscreener.com

Apr 15, 2025

Kyverna Therapeutics Files For Offering Of Up To $50 Mln Common Stock From Time To TimeSEC Filing - marketscreener.com

Apr 15, 2025

Apr 11, 2025

HC Wainwright Has Negative Outlook for KYTX Q1 Earnings - MarketBeat

Apr 11, 2025

Apr 08, 2025

HC Wainwright Cuts Kyverna Therapeutics (NASDAQ:KYTX) Price Target to $4.00 - MarketBeat

Apr 08, 2025

Apr 07, 2025

KYTX stock plunges to 52-week low, touches $1.85 amid market rout - Investing.com Australia

Apr 07, 2025

KYTX stock plunges to 52-week low, touches $1.85 amid market rout By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 05, 2025

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Average Recommendation of "Buy" by Analysts - MarketBeat

Apr 05, 2025

Morgan Stanley Has Lowered Expectations for Kyverna Therapeutics (NASDAQ:KYTX) Stock Price - MarketBeat

Apr 05, 2025

Apr 03, 2025

Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025KYTX - ACCESS Newswire

Apr 03, 2025

H.C. Wainwright cuts Kyverna Therapeutics price target to $4 - Investing.com Australia

Apr 03, 2025

KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025

KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 03, 2025

H.C. Wainwright cuts Kyverna Therapeutics price target to $4 By Investing.com - Investing.com Canada

Apr 03, 2025

Apr 01, 2025

Kyverna Therapeutics price target lowered to $20 from $40 at Morgan Stanley - TipRanks

Apr 01, 2025

Mar 31, 2025

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT) - GlobeNewswire

Mar 31, 2025

Kyverna Therapeutics Advances CAR T-Cell Therapy Trials - MSN

Mar 31, 2025

Kyverna Therapeutics price target lowered to $12 from $13 at UBS - MSN

Mar 31, 2025

Kyverna Therapeutics (NASDAQ:KYTX) Announces Quarterly Earnings Results - MarketBeat

Mar 31, 2025

Mar 30, 2025

KYVERNA THERAPEUTICS Earnings Preview: Recent $KYTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 30, 2025

Mar 28, 2025

KYTX stock touches 52-week low at $2.2 amid sharp annual decline - Investing.com

Mar 28, 2025

Kyverna Therapeutics inks sales agreement with Jefferies By Investing.com - Investing.com Canada

Mar 28, 2025

Mar 27, 2025